Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Follow-up of EG110A in Neurogenic Detrusor Overactivity
NCT07227285Phase 2Not yet recruiting
- Sponsor
- EG 427
- Start
- Apr 2026
- Primary completion
- Apr 2031
- Modality
- Gene Editing, Gene Silencing, Herpes Simplex Vectors
- Countries
- 1
01
Overview
A Phase 2 trial of EG110A in neurogenic detrusor overactivity (NDO), sponsored by EG 427. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
EG110A
03
Conditions
neurogenic detrusor overactivity (NDO)
Beyond the preview
Go deeper on NCT07227285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07227285.